Ginsenoside Rg1 promotes fetal hemoglobin production in vitro: A potential therapeutic avenue for ß-thalassemia.

ß-thalassemia, a globally prevalent genetic disorder, urgently requires innovative treatment options. Fetal hemoglobin (HbF) induction stands as a key therapeutic approach. This investigation focused on Ginsenoside Rg1 from the Panax genus for HbF induction. Employing K562 cells and human erythroid precursor cells (ErPCs) derived from neonatal cord blood, the study tested Rg1 at different concentrations. We measured its effects on γ-globin mRNA levels and HbF expression, alongside assessments of cell proliferation and differentiation. In K562 cells, Rg1 at 400 µM significantly increased γ-globin mRNA expression by 4.24 ± 1.08-fold compared to the control. In ErPCs, the 800 µM concentration was most effective, leading to an over 80% increase in F-cells and a marked upregulation in HbF expression. Notably, Rg1 did not adversely affect cell proliferation or differentiation, with the 200 µM concentration showing an increase in γ-globin mRNA by 2.33 ± 0.58-fold, and the 800 µM concentration enhancing HbF expression by 2.59 ± 0.03-fold in K562 cells. Our results underscore Rg1's potential as an effective and safer alternative for ß-thalassemia treatment. By significantly enhancing HbF levels without cytotoxicity, Rg1 offers a notable advantage over traditional treatments like Hydroxyurea. While promising, these in vitro findings warrant further in vivo exploration to confirm Rg1's therapeutic efficacy and to unravel its underlying mechanistic pathways.

Construction and Simulation of Biomechanical Model of Human Hip Joint Muscle-Tendon Assisted by Elastic External Tendon by Hill Muscle Model.

Based on the Hill muscle model (HMM), a biomechanical model of human hip muscle tendon assisted by elastic external tendon (EET) was preliminarily established to investigate and analyze the biomechanical transition between the hip joint (HJ) and related muscle tendons. Using the HMM, the optimal muscle fiber length and muscle force scaling variables were introduced by means of constrained optimization problems and were optimized. The optimized HMM was constructed with human parameters of 170 cm and 70 kg. The biomechanical model simulation test of the hip muscle tendon was performed in the automatic dynamic analysis of mechanical systems (ADAMS) software to analyze and optimize the changes in the root mean square error (RMSE), biological moment, muscle moment distribution coefficient (MDC), muscle moment, muscle force, muscle power, and mechanical work of the activation curves of the hip major muscle, iliopsoas muscle, rectus femoris muscle, and hamstring muscle under analyzing the optimized HMM and under different EET auxiliary stiffnesses from the joint moment level, joint level, and muscle level, respectively. It was found that the trends of the output joint moment of the optimized HMM and the biological moment of the human HJ were basically the same, r 2 = 0.883 and RMSE = 0.18 Nm/kg, and the average metabolizable energy consumption of the HJ was (243.77 ± 1.59) J. In the range of 35%∼65% of gait cycle (GC), the auxiliary moment showed a significant downward trend with the increase of EET stiffness, when the EET stiffness of the human body was less than 200 Nm/rad, the biological moment of the human HJ gradually decreased with the increase of EET stiffness, and the MDC of the iliopsoas and hamstring muscles gradually decreased; when the EET stiffness was greater than 200 Nm/rad, the increase of the total moment of the extensor muscles significantly increased, the MDC of the gluteus maximus and rectus muscles gradually increased, and the gluteus maximus and hamstring muscle moments and muscle forces gradually increased; the results show that the optimized muscle model based on Hill can reflect the law of human movement and complete the simulation test of HJ movements, which provides a new idea for the analysis of energy migration in the musculoskeletal system of the lower limb.

The study on the safety and efficacy of amnion graft for preventing the recurrence of moderate to severe intrauterine adhesions.

Transcervical resection of adhesion (TCRA) is the standard treatment for the intrauterine adhesions, but the recurrence of adhesions is a tough problem for the gynecologist. In addition, the therapeutic strategy after TCRA about prevention of recurrence remains controversial especially for the patients with moderate to severe intrauterine adhesions (IUAs). Hence, we designed this study to explore the safety and efficacy of fresh amnion grafts for preventing the recurrence after TCRA for patients with moderate to severe IUAs. One hundred patients with moderate to severe IUAs who presented with a history of hypomenorrhea, amenorrhea and infertility were included in the study from January 2015 to December 2017. Patients were divided into amnion group (52 patients) and chitosan group (48 patients). Fresh amnion grafts or intrauterine injections of chitosan were administered after TCRA. Transvaginal ultrasonography (TVUS) and hysteroscopy were performed at the first and third month after the operation. The surgical procedures for all patients were completed successfully without relevant complications. In amnion group, 8 patients exhibited relapse in the first month and 2 patients in three months after surgery; in chitosan group, 23 women exhibited relapse in the first month and 18 patients in three months after surgery. Statistical analysis revealed that the recurrence rate of adhesion in amnion group was significantly lower than those of chitosan group in the first and three months after surgery (P 1  = 0.000, P 2  = 0.000). After TCRA, fresh amnion graft plays a significant role in preventing further adhesions than injections of chitosan.